Mucormycosis is the second most common mould infection, often indistinguishable from other invasive mould infections such as aspergillosis. Although an appropriate antifungal therapy is effective at an early stage of the infection, there is no reliable diagnostic method for decision making. Thus, it is necessary to develop an efficient method that can detect mucormycosis rapidly and accurately. We searched for secreted or membrane-bound proteins of Rhizopus oryzae, which is the most common pathogen of mucormycosis, using the method of a signal sequence trap by retrovirus-mediated expression (SST-REX). Among the identified proteins, a Rhizopus-specific antigen was selected as a candidate, and efficacy of this specific antigen was evaluated using R. oryzae-infected mice. Of 302 clones obtained from the SST-REX library, a hypothetical protein (23 kDa, named "protein RSA") was selected as a candidate because of its highest prevalence of clones. Protein RSA was detected at significantly higher concentrations in serum and in lung homogenates of the infected mice as compared to those of uninfected mice. Our study indicates that protein RSA may be a promising biomarker of R. oryzae infection. SST-REX may be useful for comprehensive screening of prospective eukaryotic biomarkers of intractable mould infections.
Introduction
Invasive mould infections are frequently life-threatening in immunosuppressed hosts, such as patients with a hematological cancer, a solid organ transplant, uncontrolled diabetes, or penetrating trauma. 1 Invasive mucormycosis is the second most common mold infection after invasive aspergillosis (IA), 2 and several studies showed increasing incidence of mucormycosis among the above-mentioned immunocompromised patients. 3, 4 Timely surgical treatment of the site of mucormycosis, especially of the rhino-orbitocerebral and soft tissue, is recommended to reduce the mass of the infecting mould and to prevent expansion of mucormycosis to adjacent structures. 5 Nonetheless, this surgical intervention is not recommended for most patients with hematological cancer because of severe thrombocytopenia. In addition, therapeutic options against mucormycosis are limited because voriconazole and caspofungin, which are antifungal drugs that are safer than amphotericin B, 6 are ineffective. Although posaconazole may be active against Mucorales, posaconazole monotherapy is not recommended as a first-line treatment of mucormycosis 7 and is commercially unavailable in Japan. Some reports suggest that a high dose of liposomal amphotericin B (L-AMB) is effective as a firstline treatment of mucormycosis but poses a high risk of drug-related renal toxicity. 8 In addition, mucormycosis is often indistinguishable from other invasive mould infections such as aspergillosis because the clinical and radiographic findings of pulmonary mucormycosis are nonspecific. Currently, the diagnosis of invasive mould infections is usually based on clinical-sample culture and detection of fungal hyphae during histopathological examination. In many cases, it is difficult to perform invasive examinations for the diagnosis, for example, transbronchial and surgical lung biopsies, because of the poor general condition of such patients. The Aspergillus antigen (galactomannan) test is available for IA. Some studies have shown the potential value of quantitative real-time polymerase chain reaction (qPCR) testing for circulating Mucorales DNA (cmDNA) in human serum and plasma samples for early diagnosis, 9, 10 but there are no standardized serum assays available for the detection of Mucorales-specific antigens. As a result of delayed diagnosis and intervention, prognosis of mucormycosis remains poor as compared to aspergillosis, and therefore it is important to accurately distinguish mucormycosis from IA and to commence an appropriate treatment as soon as possible.
Our main aim was to develop a rapid diagnostic test for mucormycosis. Here, we identified an antigen specific for Rhizopus oryzae, which is the most common pathogen and responsible for up to 70% of all cases of mucormycosis. 11, 12 This antigen may serve as a candidate biomarker and was identified by the method of a signal sequence trap by retrovirus-mediated expression (SST-REX). 13 Diagnostic evaluation in mice revealed this marker's efficacy.
Materials and methods
The microbe R. oryzae TIMM 1327 was originally provided by Teikyo University Institute of Medical Mycology. These isolates were grown on potato-dextrose-agar (PDA) plates for 2 weeks at 30
• C. On the day of infection, conidia were aseptically dislodged from PDA plates and resuspended in sterile saline supplemented with 0.05% of Tween 80 and passed through 70-μm nylon cell strainers (BD Falcon, Heidelberg, Germany) for removal of any hyphal fragments. The conidia were counted with a hemocytometer to prepare the final inoculum.
Cloning of the Rhizopus oryzae-specific antigen by the method of a signal sequence trap by retrovirus-mediated expression An R. oryzae complementary DNA (cDNA) library was screened by SST-REX, which detects signal sequences coded in cDNA fragments based on their ability to redirect a constitutively active mutant cytokine receptor to the cell surface, resulting in interleukin 3 (IL-3)-independent growth of Ba/F3 cells. 13 Briefly, cDNA was synthesized from total RNA of R. oryzae cells that were cultivated in the YPD medium (0.5% yeast extract, 1% peptone, 2% glucose) overnight. The synthesized cDNA was separated on the basis of size, and fractions >600 bp were inserted into BstXI sites of the pMX-SST vector by means of BstXI adapters (Invitrogen, Carlsbad, CA, USA). Ba/F3 cells were infected with high-titer retroviruses expressing the R. oryzae cDNA library, and the integrated cDNA fragments were isolated from factor-independent Ba/F3 clones by genomic PCR. All cDNA fragments were sequenced and analyzed. After that, the R. oryzae cDNA library in the pME18S vector was screened by means of the 32 P-labeled cDNA fragment of a clone to isolate the entire coding region.
The most frequent gene among the genes identified by the above method was selected as a source of the candidate protein, and this candidate protein was named "protein RSA" and used in the subsequent experiments. We developed an enzyme-linked immunosorbent assay (ELISA) based on this protein. The signal sequence was predicted by SignalP 4.1 Server (http://www.cbs.dtu.dk/services/ SignalP/). 
Animals
Six-week-old female Institute of Cancer Research (ICR) mice (>20 g) were purchased from SLC (Hamamatsu, Japan) and were allowed to acclimate for a week. They were given irradiated feed and sterile water. All experimental procedures were conducted in accordance with the Japanese Physiological Society and National Institutes of Health Guide for the Care and Use of Laboratory Animals. The study protocol was approved by the Committee on Animal Care and Use at Osaka City University. The experimental protocols were approved by the Ethics Review Committee for Animal Experimentation at Osaka City University.
Immunosuppression
The mice were injected with cortisone acetate (250 mg/kg, Wako Pure Chemical Industries, Osaka, Japan) subcutaneously on days −2 and 0 and with cyclophosphamide (100 mg/kg, Sigma-Aldrich, Tokyo, Japan) intraperitoneally on days −2, 0, and 2 ( Fig. 1 ). To prevent bacterial infection, tetracycline hydrochloride (Wako Pure Chemical Industries, Osaka, Japan) was administered with drinking water at a concentration of 0.8 mg/ml starting on day −2 of the experiment. 14 
Infection
The mice were subdivided into two groups: (i) the control group: five mice in one cage, (ii) the R. oryzae-infected group: 27 mice in five cages (including 10 mice in two cages for survival monitoring).
The control group was challenged intratracheally on day 0 with 50 μl of sterile saline containing 0.05% of Tween 80, and the R. oryzae-infected group was challenged intratracheally on day 0 with 10 7 conidia of R. oryzae (TIMM 1327) in 50 μl of sterile saline containing 0.05% of Tween 80 (Fig. 1 ). All the mice were challenged only after sedation with isoflurane.
The fungal burden in the infected lungs and a serological antigen detection test
For fungal-burden and serological examinations, the mice were killed on day 4. Blood samples were extracted from the murine heart, and the lungs were surgically removed under anesthesia. The lungs were homogenized in 1 ml of sterile normal saline after weighing, and the homogenates were quantitatively cultured on PDA plates. The resulting colonies were counted after 24-h incubation at room temperature. Homogenized lung samples were diluted 10-to 1 000 000-fold with sterile normal saline, and 100 μl of each dilution was spread on PDA plates. Thus, the detection limit was 100 colony-forming units (cfu)/ml. These values were expressed as log 10 cfu. The homogenates and blood samples were centrifuged at 1700 × g for 10 min. Serum and the supernatants of lung homogenates were used for an assay of the R. oryzae-specific antigen.
ELISA
Two custom-made polyclonal antibodies against protein RSA (which was predicted as the most abundantly secreted protein by the SST-REX method) were supplied by Medical and Biological Laboratories Co., Ltd. (formerly known as ACTGen), Nagoya, Japan. These antibodies, one for capture and the other for detection, were designed to recognize different epitopes of the antigen for a sandwich ELISA. Microtiter plates (Nunc MaxiSorp R , Thermo Fisher Scientific, Waltham, MA, USA) were coated with 100 μl of the capture antibody in 0.05 M carbonate-bicarbonate buffer (pH 9.6) at 3 μg/ml with incubation at room temperature for 2 h. The unbound antibody was removed by washing the wells 3 times with phosphate-buffered saline (PBS) containing 0.05% of Tween 20 (PBS-T). The remaining proteinbinding sites in the wells were blocked with blocking buffer (PBS containing 4% of bovine serum albumin (BSA) and 0.2 M sucrose) at 4
• C overnight. After three washes, 100 μl of serum samples diluted five-fold or of supernatants from the lung homogenates diluted five-fold in incubation buffer (PBS containing 0.1% of BSA) were added to the wells in triplicate and were incubated for 1 h at room temperature.
To construct a standard curve, serial dilutions of the recombinant antigen (protein RSA, 1.25 to 20 ng/ml) were prepared in incubation buffer containing 20% of mouse serum (Sigma-Aldrich, Tokyo, Japan). After we washed the wells, 100 μl of the biotin-conjugated detection antibody (3 μg/ml) in incubation buffer was added to each well and incubated for 1 h at room temperature. The microplates were washed, and a streptavidin/peroxidase conjugate (Pierce, Rockford, IL) diluted 1:10 000 in incubation buffer was added (100 μl/well), followed by incubation for 30 min at room temperature. The microplates were then washed, and 100 μl of the SureBlue TM TMB 1-Component
Microwell Peroxidase Substrate (KPL, Gaithersburg, MD, USA) was added to each well. The microplates were incubated for 10 min at room temperature. The reaction was stopped by addition of HCl, and absorbance was measured at 450 nm using a Multiskan-JX (Thermo Fisher Scientific, Yokohama, Japan).
Statistical analysis
All calculations were performed in the JMP software, version 10.0.0 for Windows (SAS Institute Inc., Cary, NC, USA). The statistical significance level was set to 5%. Survival curves for the mice after infection were plotted using the Kaplan-Meier analysis. To compare two groups, we performed Wilcoxon's rank-sum test, and to assess a correlation between protein RSA levels and lung weight, Spearman's rank correlation coefficient was calculated.
Results

Candidate proteins obtained by means of A signal sequence trap by retrovirus-mediated expression
We identified 302 genes encoding transmembrane and secreted proteins in the SST-REX library and selected a hypothetical protein (23 kDa) that had the highest prevalence: 163 clones (Supplementary Table 1 ). This protein was named protein RSA; it consists of 226 amino acid residues, and the first 18 residues were predicted to be a signal sequence (Table 1) . A BLASTP search indicated that this protein is unique to R. oryzae, that is, it is absent in the common pathogenic fungi such as Aspergillus spp. and Candida spp.
The survival rate of mice infected intratracheally with conidia of Rhizopus oryzae
For survival monitoring, 10 mice in two cages were infected with R. oryzae according to the same protocol as in the R. oryzae-infected group. They started to die on day 4, and only one mouse had survived until day 14, when we finished the monitoring. Median survival time was 5 days, and 10% of the mice survived (Fig. 2) . No mice died in the control group.
Survival and growth of Rhizopus oryzae in the lungs of mice
Seventeen mice in three cages were challenged intratracheally with conidia of R. oryzae for evaluation, and 16 mice had survived until they were killed (day 4). We assessed survival and growth of R. oryzae by measuring lung weight and by calculating the cfu present in the homogenized lungs (Table 2 ). Thirteen mice of the R. oryzaeinfected group yielded Rhizopus colonies in the cultures of homogenized lungs, and two mice of the R. oryzaeinfected group yielded other bacterial colonies in the cultures of homogenized lungs: a suspected coinfection. Mice without detectable hyphae were excluded from further analyses. Control mice and three mice challenged with conidia of R. oryzae had undetectable cfu. Mean log 10 cfu in Figure 2 . Kaplan-Meier probability of survival after Rhizopus oryzae infection. Survival curves for the mice after infection were plotted using Kaplan-Meier analysis. Ten mice in the R. oryzae-infected group were used for survival monitoring until day 14. Median survival time was 5 days, and only 10% of the mice survived. homogenized lungs in the R. oryzae-infected group was 5.2 (range, 2.51-5.49), and R. oryzae-infected mice showed significantly increased lung weight ( Table 2) .
Evaluation of the Rhizopus oryzae-specific antigen (protein RSA) concentration in serum
Antigen titers in serum obtained from control mice were 57.7 ± 12.3 ng/ml (mean ± SD; range 50.2-61.3 ng/ml). Antigen titers in serum obtained from R. oryzae-infected mice were 161.1 ± 117.7 ng/ml (mean ± SD; range 53.5-413.6 ng/ml), and these titers were significantly higher than those of control mice (P < .05, Fig. 3A ). Detection limit was approximately 50 ng/ml, and thus antigen titer elevation in control mice was presumed to be nonspecific. The serum antigen concentration had a tendency to correlate positively with lung weight (P = .085, r = 0.50, Fig. 4A ).
Evaluation of the protein RSA concentration in lung tissue
Antigen titers in homogenized lungs obtained from control mice were 66.1 ± 4.9 ng/ml (mean ± SD; range 62.5-76.9 ng/ml). Antigen titers in homogenized lungs of R. oryzae-infected mice were 307.0 ± 64.4 ng/ml (mean ± SD; range 95.1-426.7 ng/ml). These titers were significantly higher than those of control mice (P < .05, Fig. 3B ). Protein RSA levels in lung tissues were found to have a significant correlation with lung weight (P < .0001, r = 0.89; Fig. 4B ).
We reproduced the finding of a higher protein RSA concentration in the serum and lung tissue of R. oryzae-infected mice using the same protocol (Supplementary Table 2 ).
Discussion
Since a signal sequence trap was first reported as a cloning strategy for secreted proteins and type I membrane proteins, this method has been applied to discovery of biomarkers such as cancer markers. 15 Most studies have been conducted on mammalian cells including human ones, and only several studies examined proteins from other eukaryotic sources. Although the structure of signal sequences and the functioning of the secretory machinery are well conserved from prokaryotes to eukaryotes, 16 the above method has never been applied to fungal pathogens of humans.
Because there is not an established method for rapid diagnosis of invasive fungal infections and because it is especially difficult to distinguish aspergillosis and mucormycosis, we tried to use this method to find a novel mucormycosis biomarker. Mucors from clinical samples are generally difficult to cultivate, with the culturability rate being only 2%. 17 Diagnosis is mostly based on histopathological analysis (85.7%) and microscopy (12.3%), and therefore most cases are not accurately diagnosed. 17 Bronchoalveolar lavage (BAL), a lung biopsy, and blood and urine samples are the major clinical samples available in pulmonary invasive mycoses. BAL and a lung biopsy usually require bronchoscopy; therefore, blood and urine samples are more practical. Recently, qPCR assays for cmDNA in serum were developed for rapid detection of Mucorales, 9, 10 but a serum antigen test for Mucorales has never been reported. Our results suggest that detection of protein RSA in serum may be a promising diagnostic test for R. oryzae mucormycosis, as effective as qPCR assays. In addition, we showed that the antigen concentration is also elevated in infected murine lungs, suggesting that the antigen in the lung biopsy samples can be useful as a biomarker. Although lung antigen levels and lung weight correlated well, serum antigen concentration and lung weight did not. Because lung weight can reflect severity of pulmonary damage, so can lung antigen concentrations. On the other hand, the lack of a correlation between the serum antigen concentration and lung weight may mean that this secreted protein can be detected irrespective of the severity of lung damage because Mucorales tend to invade blood vessels, frequently resulting in thrombosis and subsequent tissue necrosis. 18, 19 Protein RSA is annotated as a hypothetical protein carrying a conserved signal sequence in the public database for R. oryzae, and secretion of this protein into the culture medium was confirmed experimentally (data not shown). BLAST analysis showed that this protein is well conserved among Rhizopus spp. but does not exist in Aspergillus spp. Because other Mucorales do not have this protein, it may serve as a specific marker of Rhizopus infection. We are currently tempted to use the SST-REX method to find specific antigens of other pathogenic filamentous fungi, including other Mucorales and Aspergillus spp. There is an established diagnostic test (involving a galactomannan antigen) for aspergillosis, but the sensitivity is inadequate. If the new assay is developed successfully, more accurate diagnosis using another antigen may lead to more accurate selection of treatment.
To determine whether the method we developed is indeed applicable to clinical practice, further studies are necessary including testing on clinical serum samples, evaluation of murine or human BAL samples and examining the possible relation between the disease severity and antigen titer. In addition, functional analysis of this protein in the pathogenesis should be conducted because this research may lead to a novel therapeutic strategy.
In conclusion, we identified an R. oryzae-specific secreted protein and showed that this protein may be a serum biomarker for early diagnosis of R. oryzae mucormycoses. Our results also suggest that SST-REX can help to identify other filamentous-fungus-specific antigens and may be applied to comprehensive screening of prospective eukaryotic biomarkers.
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